YES1

Summary

YES1 (YES proto-oncogene 1, Src family tyrosine kinase, HGNC:12841) is a protein-coding gene on chromosome 18p11.32, encoding Tyrosine-protein kinase Yes (P07947). Non-receptor protein tyrosine kinase that is involved in the regulation of cell growth and survival, apoptosis, cell-cell adhesion, cytoskeleton remodeling, and differentiation.

This gene is the cellular homolog of the Yamaguchi sarcoma virus oncogene. The encoded protein has tyrosine kinase activity and belongs to the src family of proteins. This gene lies in close proximity to thymidylate synthase gene on chromosome 18, and a corresponding pseudogene has been found on chromosome 22.

Source: NCBI Gene 7525 — RefSeq curated summary.

At a glance

• GWAS associations: 13
• Clinical variants (ClinVar): 73 total
• Druggable target: yes — 66 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_005433

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:12841
Approved symbol	YES1
Name	YES proto-oncogene 1, Src family tyrosine kinase
Location	18p11.32
Locus type	gene with protein product
Status	Approved
Aliases	Yes, c-yes, HsT441
Ensembl gene	ENSG00000176105
Ensembl biotype	protein_coding
OMIM	164880
Entrez	7525

Gene structure

Transcript identifiers

Ensembl transcripts: 24 — 22 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000314574, ENST00000577611, ENST00000577961, ENST00000581960, ENST00000584307, ENST00000892684, ENST00000892685, ENST00000892686, ENST00000892687, ENST00000892688, ENST00000892689, ENST00000925072, ENST00000925073, ENST00000925074, ENST00000925075, ENST00000925076, ENST00000925077, ENST00000925078, ENST00000925079, ENST00000925080, ENST00000945836, ENST00000945837, ENST00000945838, ENST00000945839

RefSeq mRNA: 1 — MANE Select: NM_005433 NM_005433

CCDS: CCDS11824

Canonical transcript exons

ENST00000314574 — 12 exons

Exon	Start	End
ENSE00001214226	732834	732965
ENSE00001214236	736808	736961
ENSE00001214245	739735	739811
ENSE00001214251	742918	743097
ENSE00001214256	743260	743415
ENSE00001214274	745948	746051
ENSE00001214283	747920	748018
ENSE00001214293	751705	751804
ENSE00001542048	721588	724632
ENSE00001665786	745708	745857
ENSE00002704426	812114	812242
ENSE00003596873	756557	756835

Expression profiles

Bgee: expression breadth ubiquitous, 295 present calls, max score 98.57.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 34.8243 / max 343.0358, expressed in 1669 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
170952	29.6834	1659
170953	4.2716	1411
170954	0.5509	267
170955	0.3185	146

Top tissues by expression

298 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	98.57	gold quality
oocyte	CL:0000023	98.42	gold quality
jejunal mucosa	UBERON:0000399	97.17	gold quality
parotid gland	UBERON:0001831	96.75	gold quality
buccal mucosa cell	CL:0002336	96.73	gold quality
visceral pleura	UBERON:0002401	96.55	gold quality
gingival epithelium	UBERON:0001949	96.47	gold quality
esophagus squamous epithelium	UBERON:0006920	96.43	gold quality
parietal pleura	UBERON:0002400	96.18	gold quality
pleura	UBERON:0000977	96.12	gold quality
endothelial cell	CL:0000115	96.09	gold quality
gingiva	UBERON:0001828	96.01	gold quality
squamous epithelium	UBERON:0006914	96.00	gold quality
corpus epididymis	UBERON:0004359	95.69	gold quality
mammary duct	UBERON:0001765	95.46	gold quality
oral cavity	UBERON:0000167	95.37	gold quality
skin of hip	UBERON:0001554	95.26	gold quality
epithelium of mammary gland	UBERON:0003244	95.24	gold quality
lower lobe of lung	UBERON:0008949	95.24	gold quality
nephron tubule	UBERON:0001231	95.18	gold quality
mucosa of sigmoid colon	UBERON:0004993	95.12	gold quality
choroid plexus epithelium	UBERON:0003911	95.03	gold quality
amniotic fluid	UBERON:0000173	94.91	gold quality
tibia	UBERON:0000979	94.74	gold quality
epithelium of esophagus	UBERON:0001976	94.71	gold quality
renal glomerulus	UBERON:0000074	94.70	gold quality
cartilage tissue	UBERON:0002418	94.65	gold quality
colonic mucosa	UBERON:0000317	94.54	gold quality
periodontal ligament	UBERON:0008266	94.50	gold quality
metanephric glomerulus	UBERON:0004736	94.48	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	9.16
E-MTAB-7381	no	58.50
E-CURD-112	no	3.30

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): EGR1, NANOG

miRNA regulators (miRDB)

190 targeting YES1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-507	99.97	70.11	1915
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-146A-5P	99.96	68.93	988
HSA-MIR-146B-5P	99.96	69.13	977
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-590-3P	99.96	74.34	6478

Literature-anchored findings (GeneRIF, showing 40)

• cAMP activates while Ca(2+) inhibits human sperm c-yes kinase activity (PMID:12080032)
• QM binds to c-yes at the SH3 domain in tumor cell lines (PMID:12138090)
• This review summarizes the potential functions of c-Yes and its ability to modulate signals that are distinct from c-Src. (PMID:12456296)
• Src family kinase Yes triggers hyperosmotic activation of the epidermal growth factor receptor and CD95 (PMID:15039424)
• activation of c-Yes is important for maintaining embryonic stem cells in an undifferentiated state (PMID:15148312)
• c-Yes 3’-UTR contains at least three newly identified adenine/uridine-rich elements (AREs) which are bound specifically by ARE-binding proteins HuR and AUF1. (PMID:16289864)
• Vascular endothelial growth factor (VEGF)-induced cell migration is significantly decreased in Yes-deficient retinal microvascular endothelial cells. (PMID:16400523)
• NFAT1, a transcription factor connected with breast cancer metastasis, is activated by Wnt-5a through a Ca2+ signaling pathway in human breast epithelial cells which was simultaneously counteracted by a Wnt-5a-induced Yes/Cdc42 signaling pathway. (PMID:16880514)
• activation of the protooncogene product c-Yes may play a significant role in the malignant transformation of hepatocytes (PMID:17007035)
• The results were confirmed at the level of mRNA and protein, and suggested that four genes (OPCML, RNASE1, YES1 and ACK1) could play a key role in the tumorigenesis and metastasis of gastric cancer. (PMID:17109515)
• Nucleus-located c-Yes may be a useful marker to detect early-stage hepatocellular carcinoma. (PMID:17143518)
• Amyloid aggregation by an SH3 domain from the Src family. (PMID:17418139)
• Thus, these results suggest that endogenous c-Src, c-Yes, and Lyn are differentially activated through Cdc2 activation during M phase. (PMID:17692281)
• c-Yes induction results in increased colorectal carcinoma cell motility but did not promote proliferation. In later stages of colorectal carcinogenesis, elevations in c-Yes levels/activity may promote cancer spread & metastasis rather than tumor growth. (PMID:17898870)
• Binding of CD95 Ligand to CD95 on glioblastoma cells recruit Yes and the p85 subunit of phosphatidylinositol 3-kinase to CD95, which signal invasion via the glycogen synthase kinase 3-beta pathway and subsequent expression of matrix metalloproteinases. (PMID:18328427)
• These results suggest that SFK trafficking is specified by the palmitoylation state in the SH4 domain. (PMID:19258394)
• Cloning of the complete coding sequence of the cDNA of the Csk and Yes tyrosine kinases genes of the human lymphocytes and retina have been carried out. (PMID:19757166)
• Data show that found that IFIH1, a susceptibility gene of type 1 diabetes, interacts with YES1, which plays a role in glucose transport. (PMID:19797678)
• Study identified the previously reported pathogenic mutation of NTRK3 in a KRAS/BRAF wild-type tumor and 2 somatic mutations in the Src family of kinases (YES1 and LYN) that would be expected to cause structural changes. (PMID:19893451)
• Both YES and STAT1 were verified as direct miR-145 targets (PMID:20098684)
• c-Yes was expressed in malignant melanoma, and squamous cell carcinoma type skin neoplasms. (PMID:20796316)
• Yes-associated protein may play important roles in different pathways in distinct lung tumor subtypes. (PMID:21190720)
• c-Yes regulates specific oncogenic signalling pathways important for colon cancer progression that is not shared with c-Src. (PMID:21390316)
• Functional activation of Src family kinase yes protein is essential for the enhanced malignant properties of human melanoma cells expressing ganglioside GD3. (PMID:21454696)
• Taken together, our findings demonstrate that Yes and Lyn phosphorylate EGFR at Y1101, which influences EGFR nuclear translocation in this model of cetuximab resistance. (PMID:22430206)
• study concludes that Yes is a central mediator for malignant mesothelioma cell growth that is not shared with other Src family kinases such as c-Src (PMID:22948717)
• we identified CRKL/YES as critical interrelated pathways necessary for rhabdomyosarcoma cell growth and survival and suggest a potential therapeutic role of SRC family kinase inhibition in the treatment of rhabdomyosarcoma. (PMID:23318429)
• Expression of HPV type 16 E7 resulted in increase in Src and Yes proteins level, but did not alter the level of Fyn. (PMID:23497302)
• YES1 and YAP transcript levels were higher in liver metastases of patients with colon cancer after 5FU-based neoadjuvant chemotherapy. (PMID:24323901)
• YES kinase as a proximal glucose-specific signal in the Cdc42-signaling cascade. (PMID:24610809)
• Results demonstrate a unique role for Yes in phosphorylation of FAK and in promoting PCa metastasis. Therefore, phosphorylated FAK Y861 and increased Yes expression may be predictive markers for PCa metastasis. (PMID:25868388)
• findings indicate that miR-203 induces the apoptosis of KB cells by directly targeting Yes-1, suggesting its application in anti-cancer therapeutics (PMID:25910964)
• Increased YES/SFK activation might serve as a clinical biomarker for predicting tumor resistance to IGF-1R inhibition. (PMID:25925378)
• Up-regulation of miR-210 inhibits hepatocellular carcinoma cell proliferation. Yes1 is a target of miR-210 and affects cell proliferation in HCC. (PMID:26676187)
• Our results suggest that H19 functions as a competitive endogenous RNA (ceRNA) by acting as a sink for miR-17-5p, revealing a potential ceRNA regulatory network involving H19 and miR-17-5p with a role in the modulation of YES1 expression (PMID:27093644)
• c-Yes plays an important role in migration and invasion of epithelial ovarian cancer. (PMID:27289010)
• Study on the role of miR-140-5p in inhibiting tumorigenesis in gastric cancer thru targeting YES proto-oncogene 1(YES1). (PMID:28818100)
• The downregulation of miR-199a contributes to paclitaxel (PTX) resistance in prostate cancer. YES1 mediates the regulation of miR-199a in prostate cancer PTX resistance. (PMID:29204706)
• findings identify acquired amplification of YES1 as a recurrent and targetable mechanism of resistance to EGFR inhibition in EGFR-mutant lung cancers and demonstrate the utility of transposon mutagenesis in discovering clinically relevant mechanisms of drug resistance. (PMID:29875142)
• YES1 is essential for NSCLC carcinogenesis. YES1 overexpression induced metastatic spread in preclinical in vivo models. YES1 genetic depletion by CRISPR/Cas9 technology significantly reduced tumor growth and metastasis. (PMID:31166114)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	yes1	ENSDARG00000005941
mus_musculus	Yes1	ENSMUSG00000014932
rattus_norvegicus	Yes1	ENSRNOG00000037227

Paralogs (32): FGR (ENSG00000000938), MATK (ENSG00000007264), BTK (ENSG00000010671), FYN (ENSG00000010810), STYK1 (ENSG00000060140), TNK2 (ENSG00000061938), TXK (ENSG00000074966), JAK2 (ENSG00000096968), ABL1 (ENSG00000097007), PTK6 (ENSG00000101213), HCK (ENSG00000101336), BMX (ENSG00000102010), CSK (ENSG00000103653), TYK2 (ENSG00000105397), JAK3 (ENSG00000105639), FRK (ENSG00000111816), ITK (ENSG00000113263), ZAP70 (ENSG00000115085), PTK2B (ENSG00000120899), SRMS (ENSG00000125508), TEC (ENSG00000135605), BLK (ENSG00000136573), ABL2 (ENSG00000143322), FER (ENSG00000151422), JAK1 (ENSG00000162434), SYK (ENSG00000165025), PTK2 (ENSG00000169398), TNK1 (ENSG00000174292), FES (ENSG00000182511), LCK (ENSG00000182866), SRC (ENSG00000197122), LYN (ENSG00000254087)

Protein

Protein identifiers

Tyrosine-protein kinase Yes — P07947 (reviewed: P07947)

Alternative names: Proto-oncogene c-Yes, p61-Yes

All UniProt accessions (2): P07947, J3QRU1

UniProt curated annotations — full annotation on UniProt →

Function. Non-receptor protein tyrosine kinase that is involved in the regulation of cell growth and survival, apoptosis, cell-cell adhesion, cytoskeleton remodeling, and differentiation. Stimulation by receptor tyrosine kinases (RTKs) including EGFR, PDGFR, CSF1R and FGFR leads to recruitment of YES1 to the phosphorylated receptor, and activation and phosphorylation of downstream substrates. Upon EGFR activation, promotes the phosphorylation of PARD3 to favor epithelial tight junction assembly. Participates in the phosphorylation of specific junctional components such as CTNND1 by stimulating the FYN and FER tyrosine kinases at cell-cell contacts. Upon T-cell stimulation by CXCL12, phosphorylates collapsin response mediator protein 2/DPYSL2 and induces T-cell migration. Participates in CD95L/FASLG signaling pathway and mediates AKT-mediated cell migration. Plays a role in cell cycle progression by phosphorylating the cyclin-dependent kinase 4/CDK4 thus regulating the G1 phase. Also involved in G2/M progression and cytokinesis. Catalyzes phosphorylation of organic cation transporter OCT2 which induces its transport activity.

Subunit / interactions. Interacts with YAP1 and CSF1R. Interacts with CTNND1; this interaction allows YES1-mediated activation of FYN and FER and subsequent phosphorylation of CTNND1. Interacts with FASLG. Interacts with IL6ST/gp130. Interacts with SCRIB, when YES1 is in a closed conformation; the interaction facilitates YES1 autophosphorylation.

Subcellular location. Cell membrane. Cytoplasm. Cytoskeleton. Microtubule organizing center. Centrosome. Cytosol. Cell junction.

Tissue specificity. Expressed in the epithelial cells of renal proximal tubules and stomach as well as hematopoietic cells in the bone marrow and spleen in the fetal tissues. In adult, expressed in epithelial cells of the renal proximal tubules and present in keratinocytes in the basal epidermal layer of epidermis.

Post-translational modifications. Phosphorylated. Phosphorylation by CSK on the C-terminal tail maintains the enzyme in an inactive state. Autophosphorylation at Tyr-426 maintains enzyme activity by blocking CSK-mediated inhibition. Palmitoylation at Cys-3 promotes membrane localization.

Similarity. Belongs to the protein kinase superfamily. Tyr protein kinase family. SRC subfamily.

RefSeq proteins (1): NP_005424* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000719	Prot_kinase_dom	Domain
IPR000980	SH2	Domain
IPR001245	Ser-Thr/Tyr_kinase_cat_dom	Domain
IPR001452	SH3_domain	Domain
IPR008266	Tyr_kinase_AS	Active_site
IPR011009	Kinase-like_dom_sf	Homologous_superfamily
IPR017441	Protein_kinase_ATP_BS	Binding_site
IPR020635	Tyr_kinase_cat_dom	Domain
IPR035751	Yes_SH3	Domain
IPR036028	SH3-like_dom_sf	Homologous_superfamily
IPR036860	SH2_dom_sf	Homologous_superfamily
IPR050198	Non-receptor_tyrosine_kinases	Family

Pfam: PF00017, PF00018, PF07714

Enzyme classification (BRENDA):

• EC 2.7.10.2 — non-specific protein-tyrosine kinase (BRENDA: 41 organisms, 396 substrates, 479 inhibitors, 43 Km, 32 kcat entries)

Substrate kinetics (BRENDA)

6 substrates with measured Km, best-characterized 6. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
ATP	0.014–17.64	12
[KDSRC KINASE]-L-TYROSINE	0.0057–0.24	12
POLY(GLU4-TYR)	0.018–0.659	10
EEEEYIQ[DP]-8-HYDROXY-5-(N,N-DIMETHYLSULFONAMIDO	0.057	1
S1 PEPTIDE	0.037	1
EEEEY	—	0

Catalyzed reactions (Rhea), 1 shown:

• L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + ADP + H(+) (RHEA:10596)

UniProt features (30 total): modified residue 8, strand 5, domain 3, lipid moiety-binding region 2, sequence variant 2, binding site 2, initiator methionine 1, chain 1, mutagenesis site 1, turn 1, helix 1, region of interest 1, compositionally biased region 1, active site 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
2HDA	X-RAY DIFFRACTION	1.9

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P07947-F1	83.19	0.67

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 396 (proton acceptor)

Ligand- & substrate-binding residues (2): 283–291; 305

Post-translational modifications (10): 21, 32, 40, 336, 345, 426, 446, 537, 2, 3

Mutagenesis-validated functional residues (1):

Position	Phenotype
426	about 50% loss of csk-mediated inhibition.

Function

Pathways and Gene Ontology

Reactome pathways

17 pathways

ID	Pathway
R-HSA-1227986	Signaling by ERBB2
R-HSA-1433557	Signaling by SCF-KIT
R-HSA-1433559	Regulation of KIT signaling
R-HSA-2029481	FCGR activation
R-HSA-210990	PECAM1 interactions
R-HSA-2682334	EPH-Ephrin signaling
R-HSA-389356	Co-stimulation by CD28
R-HSA-389513	Co-inhibition by CTLA4
R-HSA-3928662	EPHB-mediated forward signaling
R-HSA-3928663	EPHA-mediated growth cone collapse
R-HSA-3928665	EPH-ephrin mediated repulsion of cells
R-HSA-8940973	RUNX2 regulates osteoblast differentiation
R-HSA-912631	Regulation of signaling by CBL
R-HSA-9664323	FCGR3A-mediated IL10 synthesis
R-HSA-9664422	FCGR3A-mediated phagocytosis
R-HSA-9670439	Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
R-HSA-9680350	Signaling by CSF1 (M-CSF) in myeloid cells

MSigDB gene sets: 388 (showing top): GGGACCA_MIR133A_MIR133B, GOBP_REGULATION_OF_CELL_ACTIVATION, GOBP_CARBOHYDRATE_TRANSPORT, REACTOME_INNATE_IMMUNE_SYSTEM, GOBP_REGULATION_OF_INFLAMMATORY_RESPONSE_TO_ANTIGENIC_STIMULUS, DORSAM_HOXA9_TARGETS_UP, GOBP_CIRCULATORY_SYSTEM_PROCESS, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GOBP_INFLAMMATORY_RESPONSE, GOBP_CELLULAR_RESPONSE_TO_LIPID, TGCACTT_MIR519C_MIR519B_MIR519A, HOFMANN_CELL_LYMPHOMA_UP, PID_NETRIN_PATHWAY, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN

GO Biological Process (15): negative regulation of inflammatory response to antigenic stimulus (GO:0002862), cell surface receptor protein tyrosine kinase signaling pathway (GO:0007169), regulation of D-glucose transmembrane transport (GO:0010827), cell differentiation (GO:0030154), T cell costimulation (GO:0031295), cellular response to platelet-derived growth factor stimulus (GO:0036120), protein modification process (GO:0036211), Fc-gamma receptor signaling pathway involved in phagocytosis (GO:0038096), regulation of vascular permeability (GO:0043114), positive regulation of transcription by RNA polymerase II (GO:0045944), ephrin receptor signaling pathway (GO:0048013), leukocyte migration (GO:0050900), cellular response to retinoic acid (GO:0071300), cellular response to transforming growth factor beta stimulus (GO:0071560), protein phosphorylation (GO:0006468)

GO Molecular Function (12): phosphotyrosine residue binding (GO:0001784), protein tyrosine kinase activity (GO:0004713), non-membrane spanning protein tyrosine kinase activity (GO:0004715), signaling receptor binding (GO:0005102), ATP binding (GO:0005524), enzyme binding (GO:0019899), transmembrane transporter binding (GO:0044325), nucleotide binding (GO:0000166), protein kinase activity (GO:0004672), protein binding (GO:0005515), kinase activity (GO:0016301), transferase activity (GO:0016740)

GO Cellular Component (11): Golgi apparatus (GO:0005794), centrosome (GO:0005813), cytosol (GO:0005829), actin filament (GO:0005884), plasma membrane (GO:0005886), focal adhesion (GO:0005925), extracellular exosome (GO:0070062), cytoplasm (GO:0005737), cytoskeleton (GO:0005856), membrane (GO:0016020), anchoring junction (GO:0070161)

Reactome top-level categories

Rollup of top-13 pathways:

Category	Pathways
EPH-Ephrin signaling	3
Signaling by Receptor Tyrosine Kinases	2
Regulation of T cell activation by CD28 family	2
Signaling by SCF-KIT	1
Fcgamma receptor (FCGR) dependent phagocytosis	1
Cell surface interactions at the vascular wall	1
Axon guidance	1
RUNX2 regulates bone development	1
Interleukin-3, Interleukin-5 and GM-CSF signaling	1
Anti-inflammatory response favouring Leishmania parasite infection	1
Leishmania phagocytosis	1
Signaling by KIT in disease	1
Cytokine Signaling in Immune system	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein binding	3
cellular anatomical structure	3
cellular response to growth factor stimulus	2
cytoplasm	2
inflammatory response to antigenic stimulus	1
regulation of inflammatory response to antigenic stimulus	1
negative regulation of inflammatory response	1
negative regulation of immune response	1
enzyme-linked receptor protein signaling pathway	1
regulation of transmembrane transport	1
D-glucose transmembrane transport	1
cellular developmental process	1
lymphocyte costimulation	1
positive regulation of T cell activation	1
response to platelet-derived growth factor	1
protein metabolic process	1
macromolecule modification	1
Fc receptor mediated stimulatory signaling pathway	1
phagocytosis	1
Fc-gamma receptor signaling pathway	1
vascular process in circulatory system	1
blood circulation	1
regulation of biological quality	1
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
positive regulation of DNA-templated transcription	1
cell surface receptor protein tyrosine kinase signaling pathway	1
immune system process	1
cell migration	1
response to retinoic acid	1
cellular response to lipid	1
cellular response to oxygen-containing compound	1
response to transforming growth factor beta	1
phosphorylation	1
protein modification process	1
protein phosphorylated amino acid binding	1
protein kinase activity	1
protein tyrosine kinase activity	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1

Protein interactions and networks

STRING

2582 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
YES1	YAP1	P46937	936
YES1	TBX5	Q99593	756
YES1	TYMS	P04818	752
YES1	ADRA2C	P18825	691
YES1	EGFR	P00533	612
YES1	CTNNB1	P35222	566
YES1	GRB2	P29354	562
YES1	OCLN	Q16625	543
YES1	TJP1	Q07157	527
YES1	SHC1	P29353	509
YES1	CDC42	P21181	501
YES1	CAV1	Q03135	482
YES1	PTPN13	Q12923	475
YES1	MAP2K1	Q02750	456
YES1	MAP2K2	P36507	447

IntAct

447 interactions, top by confidence:

A	B	Type	Score
YES1	SOCS3	psi-mi:“MI:0915”(physical association)	0.720
PTK2	YES1	psi-mi:“MI:0915”(physical association)	0.720
YES1	FXR2	psi-mi:“MI:0915”(physical association)	0.720
YES1	TRAF2	psi-mi:“MI:0915”(physical association)	0.720
YES1	ZBTB8A	psi-mi:“MI:0915”(physical association)	0.720
YES1	SSBP3	psi-mi:“MI:0915”(physical association)	0.720
YES1	THAP1	psi-mi:“MI:0915”(physical association)	0.720
YES1	TRAF6	psi-mi:“MI:0915”(physical association)	0.720
SSBP3	YES1	psi-mi:“MI:0915”(physical association)	0.720
TRAF6	YES1	psi-mi:“MI:0915”(physical association)	0.720
SOCS3	YES1	psi-mi:“MI:0915”(physical association)	0.720
THAP1	YES1	psi-mi:“MI:0915”(physical association)	0.720

BioGRID (513): SPRR2A (Reconstituted Complex), YES1 (Two-hybrid), YES1 (Two-hybrid), YES1 (Two-hybrid), SOCS3 (Two-hybrid), FXR2 (Two-hybrid), SSBP3 (Two-hybrid), THAP1 (Two-hybrid), NIF3L1 (Two-hybrid), C1orf94 (Two-hybrid), FUNDC1 (Two-hybrid), ZBTB8A (Two-hybrid), YES1 (Affinity Capture-MS), YES1 (Affinity Capture-MS), YES1 (Affinity Capture-MS)

ESM2 similar proteins: A0JNB0, A1A5H8, A1Y2K1, F1LM93, F1RDG9, P00523, P00524, P00525, P00526, P00527, P05480, P06239, P06240, P06241, P07947, P07948, P08103, P08631, P09324, P09769, P10936, P12931, P13115, P13116, P13406, P14084, P14085, P14234, P17713, P25020, P27446, P27447, P31693, P39688, P42683, P50545, P63185, Q01621, Q02977, Q04736

Diamond homologs: A0JNB0, A1A5H8, A1Y2K1, F1LM93, F1RDG9, G5EE56, O45539, P00519, P00520, P00521, P00522, P00523, P00524, P00525, P00526, P00527, P00528, P00544, P03949, P05480, P06239, P06240, P06241, P07947, P07948, P08103, P08630, P08631, P09324, P09769, P10447, P10936, P12931, P13115, P13116, P13406, P14084, P14085, P14234, P15054

SIGNOR signaling

18 interactions.

A	Effect	B	Mechanism
YES1	down-regulates	CDK4	phosphorylation
YES1	“up-regulates activity”	YES1	phosphorylation
YES1	“up-regulates activity”	WBP2	phosphorylation
YES1	“down-regulates activity”	YY1	phosphorylation
YES1	“up-regulates quantity by stabilization”	SOCS1	phosphorylation
AXL	“up-regulates activity”	YES1	phosphorylation
EPHA2	“up-regulates activity”	YES1	phosphorylation
YES1	“up-regulates activity”	YAP1	phosphorylation
YES1	“up-regulates activity”	WWTR1	phosphorylation
IL6ST	“up-regulates activity”	YES1	phosphorylation
YES1	“up-regulates activity”	ANXA2	phosphorylation
YES1	“up-regulates activity”	POU2F2	phosphorylation
RPL10	down-regulates	YES1	binding
YES1	“up-regulates activity”	GLO1	phosphorylation
YES1	“down-regulates activity”	SOCS1	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 128 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Signaling by PTK6	5	33.2×	1e-04
Signaling by Non-Receptor Tyrosine Kinases	5	33.2×	1e-04
Downstream signal transduction	5	23.2×	5e-04
Signaling by BRAF and RAF1 fusions	5	10.4×	5e-03
Extra-nuclear estrogen signaling	5	10.4×	5e-03
VEGFA-VEGFR2 Pathway	6	10.2×	3e-03
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	6	7.1×	7e-03
PIP3 activates AKT signaling	8	6.5×	3e-03

GO biological processes:

GO term	Partners	Fold	FDR
regulation of cell growth	6	12.1×	2e-03
cell surface receptor protein tyrosine kinase signaling pathway	7	11.1×	2e-03
T cell receptor signaling pathway	7	9.7×	2e-03
regulation of apoptotic process	11	8.3×	8e-05
negative regulation of gene expression	9	5.7×	4e-03
cell migration	10	5.6×	2e-03

Disease & clinical

Cancer significance

Clinical variants and AI predictions

ClinVar

73 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	56
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2531 predictions. Top by Δscore:

Variant	Effect	Δscore
18:724630:TAC:T	acceptor_gain	1.0000
18:736802:TTTTA:T	donor_loss	1.0000
18:736803:TTTA:T	donor_loss	1.0000
18:736804:TTACC:T	donor_loss	1.0000
18:736805:TACC:T	donor_loss	1.0000
18:736806:A:T	donor_loss	1.0000
18:736807:CCTTG:C	donor_loss	1.0000
18:736958:CAAT:C	acceptor_gain	1.0000
18:736960:AT:A	acceptor_gain	1.0000
18:736962:C:CC	acceptor_gain	1.0000
18:736963:T:C	acceptor_gain	1.0000
18:736963:T:TC	acceptor_gain	1.0000
18:739731:ATAC:A	donor_loss	1.0000
18:739732:TAC:T	donor_loss	1.0000
18:739733:A:AT	donor_loss	1.0000
18:739734:CC:C	donor_loss	1.0000
18:739813:T:C	acceptor_loss	1.0000
18:739835:A:C	acceptor_gain	1.0000
18:742915:TACCT:T	donor_loss	1.0000
18:742916:A:AC	donor_gain	1.0000
18:742916:AC:A	donor_gain	1.0000
18:742916:ACC:A	donor_loss	1.0000
18:742917:C:CC	donor_gain	1.0000
18:742917:CC:C	donor_gain	1.0000
18:742917:CCT:C	donor_gain	1.0000
18:742917:CCTT:C	donor_gain	1.0000
18:743093:TGTTC:T	acceptor_gain	1.0000
18:743094:GTTC:G	acceptor_gain	1.0000
18:743095:TTC:T	acceptor_gain	1.0000
18:743095:TTCCT:T	acceptor_loss	1.0000

AlphaMissense

3527 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
18:724447:A:G	Y537H	1.000
18:724499:A:C	F519L	1.000
18:724499:A:T	F519L	1.000
18:724500:A:G	F519S	1.000
18:724501:A:G	F519L	1.000
18:724501:A:T	F519I	1.000
18:724508:T:A	R516S	1.000
18:724508:T:G	R516S	1.000
18:724509:C:A	R516I	1.000
18:724509:C:G	R516T	1.000
18:724510:T:C	R516G	1.000
18:724531:A:G	W509R	1.000
18:724531:A:T	W509R	1.000
18:724584:A:G	M491T	1.000
18:724611:A:G	L482S	1.000
18:732840:A:C	Y473D	1.000
18:732840:A:G	Y473H	1.000
18:732840:A:T	Y473N	1.000
18:732842:G:C	P472R	1.000
18:732842:G:T	P472Q	1.000
18:732843:G:A	P472S	1.000
18:732843:G:T	P472T	1.000
18:732851:C:A	G469V	1.000
18:732851:C:T	G469D	1.000
18:732852:C:G	G469R	1.000
18:732863:A:G	L465P	1.000
18:732867:C:T	E464K	1.000
18:732875:A:G	L461P	1.000
18:732881:C:A	G459V	1.000
18:732881:C:T	G459E	1.000

dbSNP variants (sampled 300 via entrez): RS1000033153 (18:780994 G>C), RS1000041115 (18:722911 T>A,C), RS1000060924 (18:806223 C>A,T), RS1000070719 (18:806439 A>C,G), RS1000113407 (18:727768 A>G), RS1000115534 (18:741729 G>C), RS1000120993 (18:728315 C>T), RS1000146467 (18:766246 C>G), RS1000157730 (18:794598 C>G,T), RS1000202568 (18:806598 G>A), RS1000240477 (18:814145 T>A,G), RS1000305583 (18:754616 C>A), RS1000313116 (18:814306 C>A,G), RS1000338429 (18:733026 G>A), RS1000339486 (18:730691 C>T)

Disease associations

OMIM: gene MIM:164880 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

13 associations (top):

Study	Trait	p-value
GCST001918_3	Pulmonary function in asthmatics	4.000000e-06
GCST002279_44	PR interval in Tripanosoma cruzi seropositivity	3.000000e-07
GCST005024_83	Pursuit maintenance gain	6.000000e-06
GCST005978_3	Diastolic blood pressure	7.000000e-10
GCST005979_4	Systolic blood pressure	5.000000e-11
GCST006010_17	Mean arterial pressure	3.000000e-12
GCST006624_106	Systolic blood pressure	2.000000e-21
GCST007267_39	Systolic blood pressure	6.000000e-16
GCST007703_77	Systolic blood pressure	3.000000e-11
GCST007704_29	Diastolic blood pressure	1.000000e-08
GCST007706_39	Mean arterial pressure	4.000000e-11
GCST007707_40	Hypertension	7.000000e-07
GCST009888_1	Thyroid autoantibody positivity (anti-thyroglobulin (TgAb) and/or anti-thyroid peroxidase (TPOAb) levels)	2.000000e-08

EFO canonical traits (6, from GWAS)

EFO ID	Trait name
EFO:0003892	pulmonary function measurement
EFO:0004462	PR interval
EFO:0008433	pursuit maintenance gain measurement
EFO:0006336	diastolic blood pressure
EFO:0006335	systolic blood pressure
EFO:0006340	mean arterial pressure

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (3): CHEMBL2073 (SINGLE PROTEIN), CHEMBL2363074 (PROTEIN FAMILY), CHEMBL4523728 (PROTEIN-PROTEIN INTERACTION)

Molecules with ChEMBL bioactivity

66 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 433,199 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1171837	PONATINIB	4	8,955
CHEMBL1287853	FEDRATINIB	4	3,554
CHEMBL1289926	AXITINIB	4	15,732
CHEMBL1421	DASATINIB ANHYDROUS	4	55,003
CHEMBL180022	NERATINIB	4	9,404
CHEMBL1834657	INFIGRATINIB PHOSPHATE	4	285
CHEMBL1852688	INFIGRATINIB	4	2,209
CHEMBL1873475	IBRUTINIB	4	7,994
CHEMBL2028663	DABRAFENIB	4	12,430
CHEMBL24828	VANDETANIB	4	42,230
CHEMBL255863	NILOTINIB	4	38,627
CHEMBL288441	BOSUTINIB	4	12,255
CHEMBL3301622	GILTERITINIB	4	2,395
CHEMBL3545311	BRIGATINIB	4	5,634
CHEMBL477772	PAZOPANIB	4	15,540
CHEMBL502835	NINTEDANIB	4	8,545
CHEMBL535	SUNITINIB	4	79,020
CHEMBL5416410	DASATINIB	4	655
CHEMBL553	ERLOTINIB	4	108,300
CHEMBL576982	QUIZARTINIB	4	4,432
CHEMBL601719	CRIZOTINIB	4
CHEMBL608533	MIDOSTAURIN	4
CHEMBL1908391	MASITINIB	3
CHEMBL217092	SARACATINIB	3
CHEMBL31965	CANERTINIB	3
CHEMBL3544983	TESEVATINIB	3
CHEMBL491473	CEDIRANIB	3
CHEMBL50	QUERCETIN	3
CHEMBL522892	DOVITINIB	3
CHEMBL572881	MOTESANIB	3

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — Src family

Most potent curated ligand interactions (9 total), top 9:

Ligand	Action	Affinity	Parameter
eCF506	Inhibition	9.3	pIC50
rebastinib	Inhibition	8.82	pIC50
saracatinib	Inhibition	8.4	pIC50
ibrutinib	Inhibition	8.39	pIC50
nemtabrutinib	Inhibition	8.38	pIC50
nefextinib	Inhibition	8.24	pIC50
SU6656	Inhibition	7.7	pIC50
xiliertinib	Inhibition	6.48	pIC50
spebrutinib	Inhibition	6.14	pIC50

Binding affinities (BindingDB)

78 measured of 99 human assays (99 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
1-[2-(4-methylphenyl)-5-tert-butyl-pyrazol-3-yl]-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea	KD	0.37 nM
IBRUTINIB	IC50	0.8 nM	US-9278100: Inhibitors of bruton’s tyrosine kinase for the treatment of solid tumors
N-[4-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]cyclohexyl]prop-2-enamide	IC50	1.1 nM	US-9278100: Inhibitors of bruton’s tyrosine kinase for the treatment of solid tumors
Staurosporine	KD	1.7 nM
N-[3-(diethylaminomethoxy)phenyl]-7-(2,6-dimethylphenyl)-5-methyl-1,2,4-benzotriazin-3-amine	IC50	2.6 nM	US-8481536: Benzotriazine inhibitors of kinases
5-(2,6-dichlorophenyl)-2-(2,4-difluorophenyl)sulfanylpyrimido[1,6-b]pyridazin-6-one	KD	2.8 nM
3-[[2-[3-(morpholin-4-ylmethyl)phenyl]thieno[3,2-b]pyridin-7-yl]amino]phenol	IC50	5.1 nM	US-9062066: Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases and pharmaceutical composition containing same
3-[[7-(2-chloro-5-hydroxyphenyl)-5-methyl-1,2,4-benzotriazin-3-yl]amino]-N-[2-(dimethylamino)ethyl]benzamide	IC50	5.3 nM	US-8481536: Benzotriazine inhibitors of kinases
N-[2-[[5-chloro-2-[4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide	IC50	5.5 nM	US-12365664: Small molecule inhibitors of SRC tyrosine kinase
N-[2-[[2-[4-(4-methylpiperazin-1-yl)anilino]-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide	IC50	5.5 nM	US-12365664: Small molecule inhibitors of SRC tyrosine kinase
N-[2-[[5-(4-acetylphenyl)-2-[4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide	IC50	5.5 nM	US-12365664: Small molecule inhibitors of SRC tyrosine kinase
N-[2-[[5-(6-methoxy-3-pyridinyl)-2-[4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide	IC50	5.5 nM	US-12365664: Small molecule inhibitors of SRC tyrosine kinase
N-[2-[[2-[4-(4-methylpiperazin-1-yl)anilino]-5-thiophen-2-ylpyrimidin-4-yl]amino]phenyl]prop-2-enamide	IC50	5.5 nM	US-12365664: Small molecule inhibitors of SRC tyrosine kinase
N-[2-[[2-[4-(4-methylpiperazin-1-yl)anilino]-5-[(4-phenoxyphenyl)methoxy]pyrimidin-4-yl]amino]phenyl]prop-2-enamide	IC50	5.5 nM	US-12365664: Small molecule inhibitors of SRC tyrosine kinase
N-(2-chloro-6-methylphenyl)-2-[3-methyl-4-(4-methylpiperazin-1-yl)anilino]-4-[2-(prop-2-enoylamino)anilino]pyrimidine-5-carboxamide	IC50	5.5 nM	US-12365664: Small molecule inhibitors of SRC tyrosine kinase
N-(2-chloro-6-methylphenyl)-2-[4-(4-methylpiperazin-1-yl)anilino]-4-[2-(propanoylamino)anilino]pyrimidine-5-carboxamide	IC50	5.5 nM	US-12365664: Small molecule inhibitors of SRC tyrosine kinase
N-[2-[[5-(furan-3-yl)-2-[4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide	IC50	5.5 nM	US-12365664: Small molecule inhibitors of SRC tyrosine kinase
N-(2-chloro-6-methylphenyl)-2-[4-(4-methylpiperazin-1-yl)anilino]-4-[2-(prop-2-enoylamino)anilino]pyrimidine-5-carboxamide	IC50	5.5 nM	US-12365664: Small molecule inhibitors of SRC tyrosine kinase
N-[2-[[5-[(4-methylphenyl)methoxy]-2-[4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide	IC50	5.5 nM	US-12365664: Small molecule inhibitors of SRC tyrosine kinase
N-[2-[[5-cyclopropyl-2-[4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide	IC50	5.5 nM	US-12365664: Small molecule inhibitors of SRC tyrosine kinase
N-[2-[[5-ethyl-2-[4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide	IC50	5.5 nM	US-12365664: Small molecule inhibitors of SRC tyrosine kinase
N-[2-[[5-bromo-2-[4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide	IC50	5.5 nM	US-12365664: Small molecule inhibitors of SRC tyrosine kinase
N-[2-[[5-methyl-2-[4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide	IC50	5.5 nM	US-12365664: Small molecule inhibitors of SRC tyrosine kinase
N-[2-[[5-iodo-2-[4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide	IC50	5.5 nM	US-12365664: Small molecule inhibitors of SRC tyrosine kinase
N-[2-[[2-[4-(4-methylpiperazin-1-yl)anilino]thieno[3,2-d]pyrimidin-4-yl]amino]phenyl]prop-2-enamide	IC50	5.5 nM	US-12365664: Small molecule inhibitors of SRC tyrosine kinase
N-(2,6-dichlorophenyl)-2-[4-(4-methylpiperazin-1-yl)anilino]-4-[2-(prop-2-enoylamino)anilino]pyrimidine-5-carboxamide	IC50	5.5 nM	US-12365664: Small molecule inhibitors of SRC tyrosine kinase
N-(2,6-dimethylphenyl)-2-[4-(4-methylpiperazin-1-yl)anilino]-4-[2-(prop-2-enoylamino)anilino]pyrimidine-5-carboxamide	IC50	5.5 nM	US-12365664: Small molecule inhibitors of SRC tyrosine kinase
N-[2-[[5-chloro-2-[4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]-5-methylphenyl]prop-2-enamide	IC50	5.5 nM	US-12365664: Small molecule inhibitors of SRC tyrosine kinase
N-[2-[[5-chloro-2-[4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]-6-methylphenyl]prop-2-enamide	IC50	5.5 nM	US-12365664: Small molecule inhibitors of SRC tyrosine kinase
N-[2-[[5-chloro-2-[4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]-3-fluorophenyl]prop-2-enamide	IC50	5.5 nM	US-12365664: Small molecule inhibitors of SRC tyrosine kinase
N-(2-chloro-6-methylphenyl)-4-[5-fluoro-2-(prop-2-enoylamino)anilino]-2-[4-(4-methylpiperazin-1-yl)anilino]pyrimidine-5-carboxamide	IC50	5.5 nM	US-12365664: Small molecule inhibitors of SRC tyrosine kinase
N-(2-chloro-6-methylphenyl)-4-[2-fluoro-6-(prop-2-enoylamino)anilino]-2-[4-(4-methylpiperazin-1-yl)anilino]pyrimidine-5-carboxamide	IC50	5.5 nM	US-12365664: Small molecule inhibitors of SRC tyrosine kinase
4-chloro-3-[6-methyl-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-benzotriazin-7-yl]phenol	IC50	5.7 nM	US-8481536: Benzotriazine inhibitors of kinases
7-(2,6-dimethylphenyl)-5-methyl-N-[3-(2-pyrrolidin-1-ylethoxy)phenyl]-1,2,4-benzotriazin-3-amine	IC50	6.4 nM	US-8481536: Benzotriazine inhibitors of kinases
N-[3-[2-[4-amino-1-(4-hydroxycyclohexyl)pyrazolo[3,4-d]pyrimidin-3-yl]ethynyl]-4-methylphenyl]-4-methyl-3-(trifluoromethyl)benzamide	IC50	10 nM	US-10266537: 3-acetylenyl-pyrazole-pyrimidine derivative, and preparation method therefor and uses thereof
BIIB-057	IC50	10.5 nM
tert-butyl 4-amino-3-[2-[2-methyl-5-[[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]carbamoyl]phenyl]ethynyl]pyrazolo[3,4-d]pyrimidine-1-carboxylate	IC50	11 nM	US-10266537: 3-acetylenyl-pyrazole-pyrimidine derivative, and preparation method therefor and uses thereof
4-chloro-3-[5-methyl-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-benzotriazin-7-yl]phenol	IC50	15.9 nM	US-8481536: Benzotriazine inhibitors of kinases
N-[3-[2-[4-amino-1-(1-methylpiperidin-4-yl)pyrazolo[3,4-d]pyrimidin-3-yl]ethynyl]-4-methylphenyl]-3-(trifluoromethyl)benzamide	IC50	18 nM	US-10266537: 3-acetylenyl-pyrazole-pyrimidine derivative, and preparation method therefor and uses thereof
7-(2,6-dimethylphenyl)-5-methyl-N-[4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-1,2,4-benzotriazin-3-amine	IC50	21 nM	US-8481536: Benzotriazine inhibitors of kinases
3-[2-[4-amino-1-(1-prop-2-enoylpiperidin-4-yl)pyrazolo[3,4-d]pyrimidin-3-yl]ethynyl]-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide	IC50	22 nM	US-10266537: 3-acetylenyl-pyrazole-pyrimidine derivative, and preparation method therefor and uses thereof
BMS-354825	KD	27 nM
4-[[7-(2-chloro-5-hydroxyphenyl)-5-methyl-1,2,4-benzotriazin-3-yl]amino]-N-(2-pyrrolidin-1-ylethyl)benzenesulfonamide	IC50	30.8 nM	US-8481536: Benzotriazine inhibitors of kinases
7-(2,6-dichlorophenyl)-5-methyl-N-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-1,2,4-benzotriazin-3-amine	IC50	40 nM	US-8481536: Benzotriazine inhibitors of kinases
N-[4-(2-cyclopentylethoxy)phenyl]-7-(2,6-dimethylphenyl)-5-methyl-1,2,4-benzotriazin-3-amine	IC50	49 nM	US-8481536: Benzotriazine inhibitors of kinases
N-(2-chloro-6-methylphenyl)-2-[3-(4-methylpiperazin-1-yl)anilino]-4-[2-(prop-2-enoylamino)anilino]pyrimidine-5-carboxamide	IC50	55 nM	US-12365664: Small molecule inhibitors of SRC tyrosine kinase
N-[2-[[2-[4-(4-methylpiperazin-1-yl)anilino]furo[3,2-d]pyrimidin-4-yl]amino]phenyl]prop-2-enamide	IC50	55 nM	US-12365664: Small molecule inhibitors of SRC tyrosine kinase
N-[2-[[6-amino-5-chloro-2-[4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide	IC50	55 nM	US-12365664: Small molecule inhibitors of SRC tyrosine kinase
N-[2-[[5-chloro-2-[4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]-4-methylphenyl]prop-2-enamide	IC50	55 nM	US-12365664: Small molecule inhibitors of SRC tyrosine kinase
7-(2-chlorophenyl)-5-methyl-N-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-1,2,4-benzotriazin-3-amine	IC50	58 nM	US-8481536: Benzotriazine inhibitors of kinases

ChEMBL bioactivities

314 potent at pChembl≥5 of 333 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.52	IC50	0.3	nM	CHEMBL400402
9.52	Kd	0.3	nM	DASATINIB
9.41	IC50	0.39	nM	CHEMBL5280844
9.40	IC50	0.4	nM	BOSUTINIB
9.30	IC50	0.5	nM	DASATINIB
9.30	IC50	0.5	nM	CHEMBL400402
9.30	IC50	0.5	nM	CHEMBL364623
9.15	IC50	0.7	nM	SARACATINIB
9.15	IC50	0.7	nM	CHEMBL3651257
9.10	IC50	0.8	nM	CHEMBL3426225
9.10	IC50	0.8	nM	CHEMBL3647967
9.05	IC50	0.89	nM	PONATINIB
9.00	Kd	1	nM	CHEMBL400402
9.00	IC50	1	nM	CHEMBL436137
9.00	IC50	1	nM	AT-9283
9.00	IC50	1	nM	CHEMBL4798527
9.00	Kd	1	nM	CHEMBL249097
8.92	IC50	1.2	nM	CHEMBL3651296
8.92	IC50	1.2	nM	CHEMBL436137
8.91	IC50	1.24	nM	CHEMBL3651228
8.89	IC50	1.28	nM	CHEMBL249821
8.89	IC50	1.3	nM	CHEMBL249821
8.89	IC50	1.3	nM	CHEMBL5268244
8.85	IC50	1.4	nM	DOVITINIB
8.82	IC50	1.5	nM	REBASTINIB
8.77	IC50	1.7	nM	STAUROSPORINE
8.70	IC50	2	nM	CHEMBL364623
8.70	IC50	2	nM	CHEMBL3426233
8.68	IC50	2.1	nM	CHEMBL2336005
8.64	IC50	2.3	nM	CHEMBL5280361
8.64	Kd	2.3	nM	CHEMBL386051
8.63	IC50	2.35	nM	STAUROSPORINE
8.62	IC50	2.39	nM	STAUROSPORINE
8.60	IC50	2.5	nM	REBASTINIB
8.59	IC50	2.6	nM	CHEMBL3651297
8.59	IC50	2.6	nM	CHEMBL218102
8.59	IC50	2.56	nM	STAUROSPORINE
8.52	IC50	3	nM	CHEMBL457614
8.52	IC50	3	nM	CHEMBL217090
8.51	IC50	3.1	nM	CHEMBL231218
8.43	IC50	3.7	nM	CHEMBL218549
8.43	Kd	3.715	nM	DASATINIB ANHYDROUS
8.40	IC50	4	nM	CHEMBL3923175
8.40	IC50	4	nM	SARACATINIB
8.40	Kd	4	nM	DASATINIB
8.40	Kd	4	nM	DASATINIB ANHYDROUS
8.40	Kd	4	nM	BOSUTINIB
8.39	IC50	4.1	nM	CHEMBL250625
8.39	IC50	4.1	nM	IBRUTINIB
8.36	IC50	4.4	nM	STAUROSPORINE

PubChem BioAssay actives

249 with measured affinity, of 2303 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide;hydrate	435328: Binding constant for YES kinase domain	kd	0.0003	uM
4-chloro-3-[5-methyl-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-benzotriazin-7-yl]phenol	325210: Inhibition of YES	ic50	0.0003	uM
(2-chloro-4-phenoxyphenyl)-[4-[[(6S)-6-(hydroxymethyl)oxan-3-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]methanone	1939138: Inhibition of YES (unknown origin)	ic50	0.0004	uM
Bosutinib	507428: Inhibition of YES1	ic50	0.0004	uM
tert-butyl N-[4-[4-amino-1-[2-[4-(dimethylamino)piperidin-1-yl]ethyl]pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]carbamate	1310132: Inhibition of human YES using poly[Glu,Tyr]4:1 as substrate in presence of [gamma-33P] ATP	ic50	0.0005	uM
N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(oxan-4-yloxy)quinazolin-4-amine	761477: Inhibition of Yes1 (unknown origin) by [gamma-33P]-ATP radiolabeled enzyme activity assay	ic50	0.0007	uM
3-[2-(4-amino-1-ethylpyrazolo[3,4-d]pyrimidin-3-yl)ethynyl]-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide	1206221: Inhibition of human Yes	ic50	0.0008	uM
Ponatinib	1716395: Binding affinity to human YES using poly[Glu:Tyr] (4:1) as substrate by radiometric hotspot kinase assay	ic50	0.0009	uM
7-(2,6-dimethylphenyl)-5-methyl-N-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-1,2,4-benzotriazin-3-amine	276183: Inhibition of Yes	ic50	0.0010	uM
N-[3-[2-[4-amino-1-(4-hydroxycyclohexyl)pyrazolo[3,4-d]pyrimidin-3-yl]ethynyl]-4-methylphenyl]-4-methyl-3-(trifluoromethyl)benzamide	1734743: Inhibition of human full length recombinant YES using poly(Glu,Tyr)4:1 as substrate incubated for 40 mins in presence of [gamma33P-ATP] by radiometric scintillation counting analysis	ic50	0.0010	uM
1-cyclopropyl-3-[5-[6-(morpholin-4-ylmethyl)-1H-benzimidazol-2-yl]-1H-pyrazol-4-yl]urea	412621: Inhibition of Yes	ic50	0.0010	uM
3-[[4-(5-hydroxy-2-methylanilino)pyrimidin-2-yl]amino]benzamide	389065: Binding affinity to human YES	kd	0.0010	uM
4-[[7-(2-chloro-5-hydroxyphenyl)-5-methyl-1,2,4-benzotriazin-3-yl]amino]-N-(2-pyrrolidin-1-ylethyl)benzenesulfonamide	325210: Inhibition of YES	ic50	0.0013	uM
[(2S,3R,4R,5R)-5-[4-amino-3-(4-methylphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]-3-methyl-4-prop-2-ynoxyoxolan-2-yl]methyl 4-fluorosulfonylbenzoate	1940020: Inhibition of YES (unknown origin)	ic50	0.0013	uM
4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one	761477: Inhibition of Yes1 (unknown origin) by [gamma-33P]-ATP radiolabeled enzyme activity assay	ic50	0.0014	uM
4-[4-[(3-tert-butyl-1-quinolin-6-ylpyrazol-5-yl)carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide	761477: Inhibition of Yes1 (unknown origin) by [gamma-33P]-ATP radiolabeled enzyme activity assay	ic50	0.0015	uM
(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one	2198460: Inhibition of human YES using poly[Glu:Tyr] (4:1) as substrate preincubated for 20 mins followed by [gamma-33P]-ATP addition and measured after 120 mins by radiometric Hot-SpotSM Kinase assay	ic50	0.0017	uM
N-(2-chloro-6-methylphenyl)-2-[(2,6-dimethylpyrimidin-4-yl)amino]-1,3-thiazole-5-carboxamide	271968: Inhibition of Yes	ic50	0.0020	uM
[(2S,3R,4R,5R)-5-[4-amino-3-(4-methylphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]-3-methyl-4-prop-2-ynoxyoxolan-2-yl]methyl ethenesulfonate	1940020: Inhibition of YES (unknown origin)	ic50	0.0023	uM
6-(2,6-dichlorophenyl)-8-methyl-2-(3-methylsulfanylanilino)pyrido[2,3-d]pyrimidin-7-one	625018: Binding constant for YES kinase domain	kd	0.0023	uM
N-(5-chloro-1,3-benzodioxol-4-yl)-5-(oxan-4-yloxy)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine	272224: Inhibition of recombinant C-YES by ELISA	ic50	0.0030	uM
5-chloro-2-N-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-4-N-(3-propan-2-yloxy-1H-pyrazol-5-yl)pyrimidine-2,4-diamine	761477: Inhibition of Yes1 (unknown origin) by [gamma-33P]-ATP radiolabeled enzyme activity assay	ic50	0.0030	uM
Dasatinib	2149796: Binding affinity to human YES1 incubated for 45 mins by Kinobead based pull down assay	kd	0.0037	uM
2-[[N-[2-[3-ethylsulfonyl-4-(4-methylpiperazin-1-yl)anilino]-5-fluoropyrimidin-4-yl]-5-(hydroxymethyl)-2-methylanilino]methyl]benzonitrile	1326072: Inhibition of N-terminal 6His-tagged full length recombinant human YES expressed in baculovirus expression system	ic50	0.0040	uM
4-chloro-3-[5-methyl-3-(4-piperidin-4-ylsulfonylanilino)-1,2,4-benzotriazin-7-yl]phenol	325210: Inhibition of YES	ic50	0.0041	uM
Ibrutinib	2188603: Inhibition of recombinant YES1 (unknown origin) preincubated for 1 hr in presence of ATP by Z-Lyte assay	ic50	0.0041	uM
4-chloro-3-[5-methyl-3-[4-(3-pyrrolidin-1-ylpropyl)anilino]-1,2,4-benzotriazin-7-yl]phenol	325210: Inhibition of YES	ic50	0.0048	uM
6-amino-7-(4-phenoxyphenyl)-9-[(3S)-1-prop-2-enoylpiperidin-3-yl]purin-8-one	1425212: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0050	uM
[4-[[7-(2-chloro-5-hydroxyphenyl)-5-methyl-1,2,4-benzotriazin-3-yl]amino]phenyl]-piperazin-1-ylmethanone	325210: Inhibition of YES	ic50	0.0052	uM
7-(2,6-dichlorophenyl)-5-methyl-N-[4-[2-(1-oxidopyrrolidin-1-ium-1-yl)ethoxy]phenyl]-1,2,4-benzotriazin-3-amine	330573: Inhibition of Yes by luminescence based kinase assay	ki	0.0060	uM
4-methyl-3-[[3-[2-(methylamino)pyrimidin-4-yl]-2-pyridinyl]oxy]-N-[3-(trifluoromethyl)phenyl]benzamide	761478: Inhibition of Yes1 (unknown origin) assessed as kinase-dependent enzymatic production of ADP from ATP using coupled luminescence-based reaction by ADP-Glo kinase assay	ic50	0.0087	uM
(3Z)-3-[[3-[3-(dimethylamino)propyl]-4,5,6,7-tetrahydro-1H-indol-2-yl]methylidene]-N-methyl-2-oxo-1H-indole-5-sulfonamide	220258: Inhibitory activity against Yes tyrosine kinase	ic50	0.0100	uM
3-[2-[(Z)-[5-(methylsulfamoyl)-2-oxo-1H-indol-3-ylidene]methyl]-4,5,6,7-tetrahydro-1H-indol-3-yl]propanamide	220258: Inhibitory activity against Yes tyrosine kinase	ic50	0.0100	uM
2-[4-[3-[2-[(Z)-[5-(methylsulfamoyl)-2-oxo-1H-indol-3-ylidene]methyl]-4,5,6,7-tetrahydro-1H-indol-3-yl]propyl]piperazin-1-yl]acetic acid	220258: Inhibitory activity against Yes tyrosine kinase	ic50	0.0100	uM
7-(2,6-dichlorophenyl)-5-methyl-N-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-1,2,4-benzotriazin-3-amine	325210: Inhibition of YES	ic50	0.0100	uM
2-[4-[3-[2-[(Z)-(5-ethylsulfonyl-2-oxo-1H-indol-3-ylidene)methyl]-4,5,6,7-tetrahydro-1H-indol-3-yl]propyl]piperazin-1-yl]acetic acid	220258: Inhibitory activity against Yes tyrosine kinase	ic50	0.0100	uM
(3Z)-3-[[3-[3-(4-hydroxypiperidin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-indol-2-yl]methylidene]-N-methyl-2-oxo-1H-indole-5-sulfonamide	220258: Inhibitory activity against Yes tyrosine kinase	ic50	0.0100	uM
(3Z)-N-methyl-3-[[3-[3-(4-methylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-indol-2-yl]methylidene]-2-oxo-1H-indole-5-sulfonamide	220258: Inhibitory activity against Yes tyrosine kinase	ic50	0.0100	uM
(3Z)-3-[[3-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]-4,5,6,7-tetrahydro-1H-indol-2-yl]methylidene]-N-methyl-2-oxo-1H-indole-5-sulfonamide	220258: Inhibitory activity against Yes tyrosine kinase	ic50	0.0100	uM
1-[2-[4-[(dimethylamino)methyl]piperidin-1-yl]ethyl]-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrazolo[3,4-d]pyrimidin-4-amine	1310132: Inhibition of human YES using poly[Glu,Tyr]4:1 as substrate in presence of [gamma-33P] ATP	ic50	0.0120	uM
4-[8-amino-3-[(6R,8aS)-3-oxo-2,5,6,7,8,8a-hexahydro-1H-indolizin-6-yl]imidazo[1,5-a]pyrazin-1-yl]-N-[4-(trifluoromethyl)-2-pyridinyl]benzamide	1721761: Inhibition of YES1 (unknown origin)	ic50	0.0120	uM
6-[4-[(4-ethylpiperazin-1-yl)methyl]phenyl]-N-[(1R)-1-phenylethyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine	761477: Inhibition of Yes1 (unknown origin) by [gamma-33P]-ATP radiolabeled enzyme activity assay	ic50	0.0131	uM
[4-[(E)-2-(1H-indazol-3-yl)ethenyl]phenyl]-piperazin-1-ylmethanone	625018: Binding constant for YES kinase domain	kd	0.0180	uM
Brigatinib	2182804: Inhibition of human YES1 using poly (Glu, Tyr)4:1 as substrate in presence of [gamma33P]-ATP by HotSpot assay	ic50	0.0190	uM
3-chloro-4-[3-(5-chloro-1,3-dioxopyrido[1,2-c]pyrimidin-2-yl)-2-methylphenyl]-7-(2-hydroxypropan-2-yl)-9H-carbazole-1-carboxamide	1678397: Inhibition of YES1 (unknown origin)	ic50	0.0190	uM
ethyl 2-[4-[3-[2-[(Z)-[5-(methylsulfamoyl)-2-oxo-1H-indol-3-ylidene]methyl]-4,5,6,7-tetrahydro-1H-indol-3-yl]propyl]piperazin-1-yl]acetate	220258: Inhibitory activity against Yes tyrosine kinase	ic50	0.0200	uM
(3Z)-5-ethylsulfonyl-3-[[3-[3-(4-hydroxypiperidin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-indol-2-yl]methylidene]-1H-indol-2-one	220258: Inhibitory activity against Yes tyrosine kinase	ic50	0.0200	uM
(3Z)-N,N-dimethyl-2-oxo-3-(4,5,6,7-tetrahydro-1H-indol-2-ylmethylidene)-1H-indole-5-sulfonamide	325713: Inhibition of Yes kinase	ic50	0.0200	uM
(3Z)-3-[[3-[3-(dimethylamino)propyl]-4,5,6,7-tetrahydro-1H-indol-2-yl]methylidene]-5-ethylsulfonyl-1H-indol-2-one	220258: Inhibitory activity against Yes tyrosine kinase	ic50	0.0200	uM
4-[8-amino-3-[(3R,6S)-1-(cyclopropanecarbonyl)-6-methylpiperidin-3-yl]imidazo[1,5-a]pyrazin-1-yl]-3-fluoro-N-[4-(trifluoromethyl)-2-pyridinyl]benzamide	1711668: Inhibition of human YES1	ic50	0.0210	uM

CTD chemical–gene interactions

64 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases expression, increases expression	2
sodium arsenite	increases abundance, increases expression	2
Arsenic	affects methylation, increases abundance, increases expression	2
Benzo(a)pyrene	decreases expression, affects methylation	2
Tobacco Smoke Pollution	affects expression, increases expression	2
aristolochic acid I	decreases expression	1
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
bisphenol F	increases expression	1
2,4,6-tribromophenol	increases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
pyrogallol 1,3-dimethyl ether	increases expression, affects cotreatment, affects localization	1
decabromobiphenyl ether	increases expression	1
11-nor-delta(9)-tetrahydrocannabinol-9-carboxylic acid	affects methylation, increases abundance	1
cobaltous chloride	increases phosphorylation, increases expression, increases secretion, decreases reaction	1
2-bromopalmitate	decreases reaction, increases abundance, increases palmitoylation	1
benzo(e)pyrene	decreases methylation	1
4-hydroxy-2-nonenal	decreases expression	1
1-hydroxypyrene	affects cotreatment, decreases methylation	1
HC toxin	increases expression	1
methacrylaldehyde	affects cotreatment, increases oxidation, increases abundance	1
dibenzo(a,l)pyrene	decreases expression	1
chromium hexavalent ion	decreases activity	1
perfluorooctane sulfonic acid	decreases expression	1
CGP 52608	affects binding, increases reaction	1
K 7174	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	increases expression	1
bisphenol B	increases expression	1
6-O-carboxypropyl-alpha-tocotrienol	decreases reaction, increases phosphorylation	1
bisphenol S	increases expression	1

ChEMBL screening assays

514 unique, capped per target: 509 binding, 3 admet, 2 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1009922	Binding	Inhibition of Yes	Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. — J Med Chem
CHEMBL2354304	Functional	PubChem BioAssay. qHTS for small molecule inhibitors of Yes1 kinase: Confirmatory screen on the cherrypicks. (Class of assay: confirmatory)	PubChem BioAssay data set
CHEMBL4313108	ADMET	Inhibition of recombinant full-length human Yes at 100 nM using poly(Glu, Tyr) 4:1 as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method	Discovery and Development of a Series of Pyrazolo[3,4-d]pyridazinone Compounds as the Novel Covalent Fibroblast Growth Factor Receptor Inhibitors by the Rational Drug Design. — J Med Chem

Cellosaurus cell lines

6 cell lines: 6 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2LK	Abcam HeLa YES1 KO	Cancer cell line	Female
CVCL_C8IN	K562/fes clone WS-1	Cancer cell line	Female
CVCL_C8IP	K562/fes clone WS-5	Cancer cell line	Female
CVCL_C8IQ	K562/fes clone WS-6	Cancer cell line	Female
CVCL_TY45	HAP1 YES1 (-) 1	Cancer cell line	Male
CVCL_TY46	HAP1 YES1 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.